CD-276-targeted Chimeric Antigen Receptor T Cell Therapy

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameCD-276-targeted Chimeric Antigen Receptor T Cell Therapy
Drug Alias NameCD276 CAR-T
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionCD276 antigen inhibitors
TargetsCD276 antigen
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShenzhen University General Hospital
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen University General Hospital
Inactive CompaniesN/A
Active IndicationsPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A